Association of MUC1 5640G>A and PSCA 5057C>T polymorphisms with the Risk of Gastric Cancer in Northern Iran

Reza Alikhani, Ali Taravati, Mohammad Bagher Hashemi-Soteh

Reza Alikhani
Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Mazandaran, Iran

Ali Taravati
Assistant Professor, Department of Molecular and Cell Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Mazandaran, Iran

Mohammad Bagher Hashemi-Soteh
Immunogenetic Research Center, Molecular and Biology Research Center, Medical Faculty, Mazandaran University of Medical, Sari, Mazandaran, Iran

hashemisoteh@gmail.com Corresponding Author
ORCiD: https://orcid.org/0000-0001-5361-520X

10.21203/rs.2.24296/v2

Subject Areas

Medical Genetics
Keywords

*Gastric cancer, Genome-Wide Association Studies (GWAS), rs4072037G>A polymorphism, rs2294008 C>T*
Abstract

Background: Gastric cancer is the fourth most common cancer worldwide and the second leading cause of cancer-related death. Genome-Wide Association Studies (GWAS) have shown that genetic diversities MUC1 (Mucin 1) and PSCA (Prostate Stem Cell Antigen) genes are involved in gastric cancer. The aim of this study was to determine the association between rs4072037G>A polymorphism in MUC1 and rs2294008 C>T in PSCA gene with gastric cancer in northern Iran.

Methods: DNA was extracted from 99 formalin fixed paraffin-embedded (FFPE) tissue samples of gastric cancer and 96 blood samples from healthy individuals (sex matched) as controls. DNA was extracted followed by PCR using specific primers. Two desired polymorphisms, 5640G>A and 5057C>T for MUC1 and PSCA genes were genotyped using PCR-RFLP method.

Results: The G allele at rs4072037 of MUC1 gene was associated with a significant decreased gastric cancer risk (OR = 0.507, 95% CI: 0.322–0.799, p = 0.003). A significant decreased risk of gastric cancer was observed in people with either AG vs AA, AG+AA vs GG and AA+GG vs AG genotypes of MUC1 polymorphism (OR = 4.296, 95% CI: 1.190–15.517, p = 0.026), (OR = 3.726, 95% CI: 2.033–6.830, p = 0.0001) and (OR = 0.223, 95% CI: 0.120–0.413, p = 0.0001) respectively. Overall, no significant association was observed between the PSCA 5057C>T polymorphism and risk of gastric cancer in all genetic models.

Conclusion: Results indicated that the MUC1 5640G>A polymorphism may have protective effect for gastric cancer and could be considered a potential molecular marker in gastric cancer in the Northern Iran population.

Background

Gastric cancer is the fourth most common cancer worldwide and the second leading cause of cancer-related death (1). The prevalence of gastric cancer varies among different geographic populations around the world (2). More than 70% of deaths from stomach cancer occur in developing countries (3, 4). Northern and northwestern regions of Iran are at high risk for gastric cancer (2). In addition, the mortality rate from stomach cancer is the first cause of death due to cancer in both sexes in Iran (5, 6). From 2000 to 2005, the incidence rate was highest in northern Provinces, including Mazandaran, Golestan, and Ardabil (2). It is believed that different environmental risk factors like alcohol consumption, smoking habits, diet and infectious agents (Helicobacter pylori) are involved in the development of gastric cancer (7-9), but a genetic predisposition to stomach cancer is unknown yet. Previous studies suggested an association between MUC1 and stomach (10), colon (11), lung (12), ovarian (13), breast (14), pancreas (15) and thyroid cancers (16). In addition, Genome-Wide Association Studies (GWAS) proposed genetic diversities like rs4072037G>A (5640G>A) in MUC1 gene and rs2294008C>T (5057C>T) polymorphisms in PSCA (Prostate Stem Cell Antigen) gene as genetic risk factors in gastric cancer (17).

MUC1 (Mucin 1) gene is located on chromosome 1q21 and includes seven exons (18). This gene encodes a membrane-bound glycoprotein with the transmembrane domain, which is attached to the upper surface of the gastrointestinal epithelium. It plays important roles in protecting epithelial surfaces against external agents (19, 20). MUC1 protein in tumor cells or tumor-associated MUC1 (TA-MUC1) differs from MUC1 expressed in normal cells, with regard to its cellular distribution, biochemical features, and function. TA-MUC1 is hypoglycosylated and overexpressed in a variety of cancers, which plays a crucial role in progression of the disease (21). It is believed that hypoglycosylation may potentiate MUC1 oncogenic signaling by decreasing its cell surface levels and increasing intracellular accumulation (21, 22).

PSCA gene is located on chromosome 8q24.3, which encodes a glycosylphosphatidyl inositol (GPI)-anchored protein with 114 amino acids. PSCA gene plays an important role in cell adhesion, proliferation, and survival (23, 24). PSCA is expressed in the epithelial cells of the bladder, stomach, kidney, skin, and esophagus. The function of PSCA in normal cells and carcinogenesis is not clearly known (25). Several reports indicated that PSCA is associated with various cancers, such as prostate (26), bladder (27), and pancreatic cancer (28). PSCA is up-
regulated in the prostate, and pancreas cancers, while in the esophagus and stomach cancers it is down-regulated (29). 5057C>T is a missense single nucleotide polymorphism (SNP) in 5'-UTR region of PSCA. This polymorphism leads to changes in transcriptional activity in the upstream regions of PSCA gene (30). The C allele changes the initiation codon from ATG to the alternative start codon ACG (threonine instead of methionine) and leads to a truncated protein lacking 9 amino acids from the N-terminus of PSCA protein. This alteration changes the protein folding and impairs intracellular processes (31).

The aim of this study is also evaluating the association between MUC1 gene polymorphism, rs4072037G>A and PSCA gene polymorphism rs2294008C>T with gastric cancer in northern Iran.

Methods

The study population

Ninety nine formalin fixed paraffin-embedded (FFPE) tissue samples (64 males and 35 females, average age 67.5 ±10.9) were collected from gastric cancer patients who referred to the pathology department of the Sari Imam Khomeini hospital from 2009 to 2016 (Table 1) (Mazandaran Province). Tumor characteristics of the patients are summarized in table 2. In addition, 96 blood samples were collected as control from healthy individuals (57 males and 39 females, average age 34.3 ± 7.0) who referred to Novin genetics laboratory of Sari for other reasons except gastric diseases (Table 1). The normal control individuals were not age-matched with patients, but they were selected randomly to find the allele/genotype frequency of the polymorphisms in the local population. Blood samples were collected in EDTA containing tubes and preserved at -20 °C. This research was approved by the ethics committee in the Mazandaran University of Medical Sciences.

DNA extraction

DNA was extracted from paraffin-embedded tissues using “YTA Genomic DNA Extraction mini kit (Yekta Tajhiz Azma, Iran) and standard salting out methods from blood samples, respectively. The extracted DNA was maintained at -20 °C until further study.

Genotyping using PCR-RFLP method

PCR (Polymerase chain reaction) was applied to amplify exon 2 of MUC1 and 5'-UTR region of PSCA genes, including desired polymorphisms using specific primers (Table 3). Each reaction consists of 2μl template DNA, 11μl ready 2x PCR master mix RED (Amplicon, Denmark), 11μl distilled water, 0.5μl of each primer at 25μM, in a total volume of 25μl. The PCR reactions were carried out under the following conditions: 94°C for 5 minutes, followed by 35 cycles 94°C for 60 seconds; 72°C for 60 seconds. The annealing temperature of 60 °C for 60 seconds was used for MUC1 gene and 56 °C for 60 seconds used for PSCA gene. PCR products were visualized on 1% agarose gel containing SYBR Safe staining. Then, PCR products were subjected to restriction digestion using 6μl of the PCR products and 5 units of restriction enzyme. Briefly, 188 bp PCR fragment of the MUC1 gene was digested using AIWNI enzyme; a homozygous GG allele remained uncut, homozygous AA genotype was digested into 114 and 74 bp fragments, and heterozygous GA produced three fragments, 118, 114 and 74 bp, respectively (Figure 1, A). Also, 139 bp PCR fragment of the PSCA gene was digested using a NlaIII restriction enzyme, genotype TT was digested to 2 fragments, 101 and 38 bp, genotype CC remained uncut and heterozygous CT showed three fragments, 139, 101 and 38 bp, respectively (Figure 1, B).

Statistical analysis

Chi-square test was used to evaluate differences in the distributions of demographic characteristics. The expected frequency of control genotypes was tested against the Hardy–Weinberg equilibrium. The odds ratio (OR) and 95% confidence interval (CI) were calculated using a logistic regression model. Ap-value < 0.05 was considered statistically significant. Otherwise, the pooled ORs and 95% CIs without adjustments were calculated for the MUC1 polymorphism rs4074037 as allele (G vs. A), homozygous genotype (GG vs. AA), heterozygous (AG vs. AA), dominant (AG+AA vs GG), recessive (AA vs AG+GG) and over-dominant model (AA+GG vs AG). For PSCA
polymorphism rs2294008, it was considered as allele (T vs. C), homozygous (TT vs. CC), heterozygous (CT vs. CC), dominant (CT+CC vs TT), recessive (CC vs CT+TT). The statistical analysis was performed using the IBM SPSS Statistics v21 software package (SPSS, Chicago, IL, USA).

Results

Demographic and clinical information of 99 patients with gastric cancer and 96 controls are shown in Tables 1 and 2, respectively. Ninety nine patient samples were genotyped for PSCA gene (rs2294008) and 91 patient samples for MUC1 gene (rs4072037) polymorphism. Genotype and allele frequencies of rs4072037 and rs2294008 and their associations with the risk of gastric cancer are presented in Tables 4 and 5, respectively.

The G allele frequency of rs4072037 is 64 % in patients with gastric cancer compared with 78 % in controls, respectively (Table 4). MUC1 rs4072037 polymorphism is associated with significant decreased gastric cancer risk in four genetic models (G vs A: OR= 0.507, 95% CI: 0.322-0.799, p=0.003; heterozygous AG compared with AA (OR= 4.296, 95% CI: 1.190-15.517, p=0.026); dominant model AG+AA vs GG (OR= 3.726, 95% CI:2.033-6.830, p=0.0001); and over-dominant model AA+GG vs AG (OR= 0.223, 95% CI: 0.120-0.413, p=0.0001) (table 4).

In the current study, no significant association was observed between the PSCA 5057C>T polymorphism and risk of gastric cancer in all genetic models (T vs C (OR= 1.050, 95% CI: 0.652 -1.693, p=0.840); homozygous TT vs CC (OR= 0.903, 95% CI: 0.327 -2.492, p=0.533); heterozygous CT vs CC (OR= 1.228, 95% CI: 0.644 -2.339, p=0.533); dominant model CT+CC vs TT (OR= 1.137, 95% CI: 0.420 -3.080, p=0.800); and recessive model CC vs CT+TT (OR= 0.904, 95% CI: 0.505 -1.620, p=0.735)). As a result, There was no statistically significant differences between the genotype and allele frequency of PSCA (5057C>T) in cases and controls in this study (table 5).

Furthermore, the result of interaction effects between MUC1 (rs4072037) and PSCA (RS2294008) genotypes with gender is summarized in table 6.

Discussion

Different studies revealed a decreased incidences of gastric cancer globally, but it is still the most common cancer in the north and northwestern parts of Iran (2). Mazandaran, Golestan, and Ardabil Provinces are high-risk areas for gastric cancer (2, 32). Gastric cancer is a multi-factorial disease; a high dietary intake of salt, the high prevalence of Helicobacter pylori (H. pylori) infection, smoking and gastroesophageal reflux disease are the environmental factors in the pathogenesis of this disease in Iran (2, 9). Among genetic risk factors, MUC1 (5640G>A) and PSCA (5057C>T) polymorphisms were reported in several studies earlier (33-36).

MUC1 is a large, transmembrane mucin glycoprotein expressed at the apical surface of most simple epithelia including stomach. Functions related to MUC1 are generally associated with mucins such as lubrication, hydration of cell surfaces, protection from microorganisms and degradative enzymes (37). MUC1 protein contains three different domains: short cytoplasmic, transmembrane and a large extracellular domain. The MUC1 gene in human is comprised of 7 exons that can be alternatively spliced to form different transcripts (37). At least twelve splice variants of MUC1 have been described (38). The SNP rs4072037G>A (5640G>A) located in the 5’ side of the second exon determines the splicing acceptor site and produce two major MUC1 transcripts. The “G” allele determines the variant type 2 or MUC1/B and contains the first 27 bp of the 2nd exon and have 9 amino acids longer than “A” allele, which create variant type 3 or MUC1/A in the N-terminal domain (39-41).

This additional sequence is potentially changing its intracellular trafficking or subsequent processing. The impact of the 9 additional amino acids of MUC1/A on the signaling functions and intracellular localization was investigated by Imbert-Fernandez and colleagues (41). They showed that COS-7 cell line transfected by plasmid containing MUC1/A or MUC1/B had similar protein expression and plasma membrane localization. This study also
showed MUC1/B and MUC1/A differs in their ability to modulate tumor necrosis α (TNFα)-induced transcription of IL-1β and IL-8, inducing the basal TGFβ expression; finally they show different inflammatory activities (41).

MUC1 could protect the gastric epithelial cells as physical barriers, so could inhibit H. pylori binding to gastric epithelial cells. The carriers of the short-short (SS) homozygous variant genotype, were at a high risk of H. pylori infection, compared to the carriers of the long-long (LL) and long-short (LS) genotypes of MUC1 variable number of tandem repeats (VNTR) (42). Miao Li and colleagues, examined the relation between H. pylori infection and three polymorphisms (rs4072037 at 1q22, rs13361707 at 5p13, and rs2274223 at 10q23) involved in the inflammatory response to the increase of gastric cancer risk. They reported that people infected by H. pylori, carrying the genotypes AA rs4072037, CT/CC rs13361707 and AG/GG rs2274223 showed an increased risk of gastric cancer (43).

**Different studies** (Hanze Zhang et al., 2011, J Kupcinskas et al., 2014) have shown that the G allele locus on rs4072037 was significantly associated with a decreased gastric cancer risk (44, 45). Xinyang Liu et al., 2014 suggested the G allele at rs4072037 of the MUC1 gene might have a protective role in people from Asian countries against gastric cancer. Also, they reported that the association was more prevalent in Asian population than in Caucasians (46).

In this study, allelic comparison (G vs A), genotype comparison (GA vs AA; GG vs AA), were done and dominant model (AG+AA vs GG), recessive model (AA vs AG+GG), over-dominant model (AA+GG vs AG) was tested (47). We found that in this study, the rs4072037 AG genotype was significantly associated with the reduced risk of gastric cancer or it plays a protecting role [odds ratios (OR) = 4.296; 95% confidence interval (CI)= 1.190-15.517, p= 0.026 for AG vs AA]

A study by Hye-Rim Song et al., 2014, with 3,245 GC cases and 700 controls suggests that the rs4072037 AG genotype was significantly associated with a reduced risk of gastric cancer [odds ratios (OR)=0.78; 95% confidence interval (CI)=0.67-0.91 for AG vs AA]. Their data indicated a significant association between the rs4072037 G allele and reduction in risk of gastric cancer (48). Another meta-analysis by Xi Guet al., 2018, which included seventeen case–control studies 12551 cases and 13436 controls, suggests that the MUC1 rs4072037 polymorphism might decrease the risk of gastric cancer in four different genetic combination (G vs. A; AG vs. AA; GG vs. AA; AG+GG vs. AA). They also performed analysis using ethnicity along with G allele and found the cancer risk was decreased among Asian population but not Caucasians (49).

Similar results (including 4,220 cases and 6,384 controls) have been obtained by Duan et al, 2014 through evaluating the association between MUC1 (rs4072037) polymorphism and gastric cancer (50). Their study demonstrated that the MUC1 (rs4072037) polymorphism is associated with risk of cancer in all genetic models (G vs A; GA vs AA; GG vs AA; AG+AA vs GG; GG vs AG+AA). They suggested MUC1 (rs4072037) polymorphism had a slightly reduced gastric cancer risk among Asian population. Also, this polymorphism was significantly associated with a decreased cancer risk in all genetic models except for homozygous recessive (AA) model in Caucasian population (50).

In this study, MUC1 rs4072037 polymorphism was significantly associated with a decreased risk of cancer in all genetic models except for homozygous GG vs AA and recessive model AG+GG vs AA(G vs A: OR= 0.507, 95%CI: 0.322-0.799, p=0.003; AG vs AA: OR= 4.296, 95%CI: 1.190-15.517, p=0.026; AG+AA vs GG: OR= 3.726, 95%CI: 2.033-6.830, p=0.0001; AA+GG vs AG: (OR= 0.223, 95% CI: 0.120-0.413, p=0.0001)). Data from this case-control study indicated that four genetic models G vs A, heterozygous GA (GA vs AA), dominant (AG+AA vs GG), over-dominant model (AA+GG vs AG), were significantly associated with the decreased risk of cancer. Therefore, **MUC1** rs4072037 polymorphism was associated with decreased risk of gastric cancer in northern Iran.

The Prostate Stem Cell Antigen (PSCA) is expressed in the gastric epithelium of the isthmus area. This area includes immature epithelial cells. PSCA expression increases in prostate cancer but it is reduced in gastric cancer and gastric intestinal metaplasia (51, 52). T allele carriers show lower transcriptional activity compared with the C allele carriers (5057C>T) in their gastric mucosa (31, 51). T allele carriers have 9 amino acids more than C allele carriers (natural protein of 114 amino acid residues) (53). The association of PSCA (5057C>T) variant was described in Korea and Japan population for the first time and the T allele was reported as a risk
factor for gastric cancer (31). A study in Japan and Korea showed that 5057T allele plays a more significant role in diffuse gastric cancer compared with the intestinal gastric cancer (31, 54). Such results were also similar in the population of Poland and the United States (34). Other studies in Caucasian and Chinese population also confirmed that this polymorphism is a risk factor for diffuse and intestinal gastric cancer (55).

In this study, PSCA rs2294008 polymorphism was not significantly associated with a increased risk of cancer in all genetic models (T vs C (OR= 1.050, 95% CI: 0.652 –1.693, p=0.840); homozygous TT vs CC (OR= 0.903, 95% CI: 0.327 –2.492, p=0.533); heterozygous CT vs CC (OR= 1.228, 95% CI: 0.644 –2.339, p=0.533); dominant model CT+CC vs TT (OR= 1.137, 95% CI: 0.420 –3.080, p=0.800); and recessive model CC vs CT+TT (OR= 0.904, 95% CI: 0.505 –1.620, p=0.735) (Table 5). Therefore, PSCA rs2294008 polymorphism was not associated with increased risk of gastric cancer in Northern Iran.

**Conclusion**

In conclusion, this study evaluated the effect of MUC1 (rs4072037) and PSCA (rs2294008) polymorphisms on GC risk in the Northern Iran population. Data from this study revealed that the MUC1 rs4072037 polymorphism was significantly associated with decreased risk of gastric cancer. However, the results could be important, especially for the interpretation of a genetic variant, which cause susceptibility to gastric cancer, and could be used as diagnostic markers in gastric cancer. In addition, PSCA polymorphism did not show any relation to gastric cancer in our findings probably because of the type of gastric cancer or the small sample size.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Ethical Committee of Mazandaran University of Medical Sciences and complied with the guidelines and principles of the Declaration. All participants signed written informed consent.

**Consent for publication**

All participants signed written informed consent for publication.

**Availability of data and material**

The datasets used and/or analyzed during the current study are available from the author for correspondence upon reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was supported by Mazandaran University of Medical Sciences.

**Authors' contributions**

Mohammad bagherHashemi-soteh conceived and designed the study.

Reza Alikhani performed the experiments.

Ali Taravati analyzed the data.

Mohammad bagherHashemi-soteh and Reza Aikhani wrote and edited the manuscript.
All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Mazandaran University of Medical Sciences for its financial support, and all the volunteers who participated in this study.

Abbreviations

GWAS: Genome-Wide Association Studies

MUC1: Mucin 1

PSCA: Prostate Stem Cell Antigen

FFPE: Formalin fixed paraffin-embedded

TA-MUC1: tumor-associated MUC1

GPI: Glycosylphosphatidylinositol

SNP: Single nucleotide polymorphism

PCR: Polymerase chain reaction

RFLP: Restriction fragment length polymorphism

H. pylori: Helicobacter pylori

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.
2. Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med. 2009;12(6):576-83.
3. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765-81.
4. Wang T, Zhang L, Li H, Wang B, Chen K. Prostate stem cell antigen polymorphisms and susceptibility to gastric cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(5):843-50.
5. Derakhshan MH, Yazdanbod A, Sadjadi AR, Shokoohi B, McColl KE, Malekzadeh R. High incidence of adenocarcinoma arising from the right side of the gastric cardia in NW Iran. Gut. 2004;53(9):1262-6.
6. Almasi Z, Rafiemanesh H, Salehiniya H. Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. Asian Pac J Cancer Prev. 2015;16(7):2757-61.
7. McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol. 2014;11(11):664-74.
8. Mocellin S, Verdi D, Pooley KA, Nitti D. Genetic variation and gastric cancer risk: a field synopsis and meta-analysis. Gut. 2015;64(8):1209-19.
9. Pourfarzi F, Whelan A, Kaldor J, Malekzadeh R. The role of diet and other environmental factors in the causation of gastric cancer in Iran--a population based study. Int J Cancer. 2009;125(8):1953-60.
10. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010;29(20):2893-904.
11. Xu Q, Yuan Y, Sun LP, Gong YH, Xu Y, Yu XW, et al. Risk of gastric cancer is associated with the MUC1 568 A/G polymorphism. Int J Oncol. 2009;35(6):1313-20.
12. Szabo E. MUC1 expression in lung cancer. Methods Mol Med. 2003;74:251-8.
13. Dong Y, Walsh MD, Cummings MC, Wright RG, Khoo SK, Parsons PG, et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol. 1997;183(3):311-7.
14. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer. 2001;91(11):1973-82.
15. Monges GM, Mathoulin-Portier MP, Acres RB, Houvenaeghel GF, Giovannini MF, Seitz JF, et al. Differential MUC1 expression in normal and neoplastic human pancreatic tissue. An immunohistochemical study of 60 samples. Am J Clin Pathol. 1999;112(5):635-40.
16. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin Tj, Childs G, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res. 2004;64(11):3780-9.
17. Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, Shu XO, et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet. 2010;42(9):764-7.
18. Zhang L, Vlad A, Milcarek C, Finn OJ. Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother. 2013;62(3):423-35.
19. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 2001;6(3):339-53.
20. Sun H, Wu X, Wu F, Li Y, Yu Z, Chen X, et al. Associations of genetic variants in the PSCA, MUC1 and PLCE1 genes with stomach cancer susceptibility in a Chinese population. PLoS One. 2015;10(2):e0117576.
21. Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20(6):332-42.
22. Altschuler Y, Kinlough CL, Poland PA, Bruns JB, Apodaca G, Weisz OA, et al. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol Biol Cell. 2000;11(3):819-31.
23. Ono H, Saeki N. Five Gastric Cancer-Susceptibility Loci Identified by Genome-Wide Association Studies J Gastroint Dig Sys 2013;S12(015):1-5.
24. Reiter RE, Gu Z, Watabe T, Thomas G, Szigiti K, Davis E, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998;95(4):1735-40.
25. Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan SR, Leach SD, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 2001;61(11):4320-4.
26. Moore ML, Teitell MA, Kim Y, Watabe T, Reiter RE, Witte ON, et al. Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate. 2008;68(2):139-51.
27. Wang S, Tang J, Wang M, Yuan L, Zhang Z. Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population. Carcinogenesis. 2010;31(4):621-4.
28. Grubbs EG, Abdel-Wahab Z, Tyler DS, Pruitt SK. Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer. Ann Surg Oncol. 2006;13(12):1645-54.
29. Yang X, Guo Z, Liu Y, Si T, Yu H, Li B, et al. Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications. Expert Rev Anticancer Ther. 2014;14(1):31-7.
30. Dudek AM, Grotenhuis AJ, Vermeulen SH, Kiemeney LA, Verhaegh GW. Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms? Int J Mol Sci. 2013;14(6):12346-66.
31. Study Group of Millennium Genome Project for C, Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet. 2008;40(6):730-40.
32. Mohebbi M, Mahmoodi M, Wolfe R, Nouri-jelyani K, Mohammad K, Zeraati H, et al. Geographical spread of gastrointestinal tract cancer incidence in the Caspian Sea region of Iran: spatial analysis of cancer registry data. BMC Cancer. 2008;8:137.
33. Song HR, Kim HN, Piao JM, Kweon SS, Choi JS, Bae WK, et al. Association of a common genetic variant in prostate stem-cell antigen with gastric cancer susceptibility in a Korean population. Mol Carcinog. 2011;50(11):871-5.
34. Lochhead P, Frank B, Hold GL, Rabkin CS, Ng MT, Vaughan TL, et al. Genetic variation in the prostate
stem cell antigen gene and upper gastrointestinal cancer in white individuals. Gastroenterology. 2011;140(2):435-41.

35. Zhang H, Jin G, Li H, Ren C, Ding Y, Zhang Q, et al. Genetic variants at 1q22 and 10q23 reproducibly associated with gastric cancer susceptibility in a Chinese population. Carcinogenesis. 2011;32(6):848-52.

36. Kupcinskas J, Wex T, Link A, Bartuseviciute R, Dedelaite M, Kevalaite G, et al. PSCA and MUC1 gene polymorphisms are associated with gastric cancer and pre-malignant gastric conditions [corrected]. Anticancer Res. 2014;34(12):7167-75.

37. Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol. 2004;2:4.

38. Williams SJ, McGuckin MA, Gotley DC, Eyre HJ, Sutherland GR, Antalis TM. Two novel mucin genes down-regulated in colorectal cancer identified by differential display. Cancer Res. 1999;59(16):4083-9.

39. Ng W, Loh AX, Teixeira AS, Pereira SP, Swallow DM. Genetic regulation of MUC1 alternative splicing in human tissues. Br J Cancer. 2008;99(6):978-85.

40. Saeki N, Sakamoto H, Yoshida T. Mucin 1 gene (MUC1) and gastric-cancer susceptibility. Int J Mol Sci. 2014;15(5):7958-73.

41. Imbert-Fernandez Y, Radde BN, Teng Y, Young WW, Jr., Hu C, Klinge CM. MUC1/A and MUC1/B splice variants differentially regulate inflammatory cytokine expression. Exp Eye Res. 2011;93(5):649-57.

42. Giraldi L, Michelazzo MB, Arzani D, Persiani R, Pastorino R, Boccia S. MUC1, MUC5AC, and MUC6 polymorphisms, Helicobacter pylori infection, and gastric cancer: a systematic review and meta-analysis. European Journal of Cancer Prevention. 2018;27(4):323-30.

43. Li M, Huang L, Qiu H, Fu Q, Li W, Yu Q, et al. Helicobacter pylori infection synergizes with three inflammation-related genetic variants in the GWASs to increase risk of gastric cancer in a Chinese population. PloS one. 2013;8(9).

44. Zhang H, Jin G, Li H, Ren C, Ding Y, Zhang Q, et al. Genetic variants at 1q22 and 10q23 reproducibly associated with gastric cancer susceptibility in a Chinese population. Carcinogenesis. 2011;32(6):848-52.

45. Kupcinskas J, Wex T, Link A, Bartuseviciute R, Dedelaite M, Kevalaite G, et al. PSCA and MUC1 gene polymorphisms are linked with gastric cancer and pre-malignant gastric conditions. Anticancer research. 2014;34(12):7167-75.

46. Liu X, Wang Z, Zhang X, Chang J, Tang W, Gan L, et al. MUC1 gene polymorphism rs4072037 and susceptibility to gastric cancer: a meta-analysis. Springerplus. 2014;3(1):599.

47. Horita N, Kaneko T. Genetic model selection for a case–control study and a meta-analysis. Meta gene. 2015;5:1-8.

48. Song H-R, Kim HN, Kweon S-S, Choi J-S, Shim HJ, Cho SH, et al. Common genetic variants at 1q22 and 10q23 and gastric cancer susceptibility in a Korean population. Tumor Biology. 2014;35(4):3133-7.

49. Gu X, Feng J, Liu L, Lu M, Ma X, Cao Y, et al. Association of MUC1 rs4072037 Functional Polymorphism and Cancer Risk: Evidence from 12551 Cases and 13436 Controls. Journal of Cancer. 2018;9(18):3343.

50. Duan F, Song C, Dai L, Cui S, Zhang X, Zhao X. The effect of MUC1 rs4072037 functional polymorphism on cancer susceptibility: evidence from published studies. PloS one. 2014;9(4):e95651.

51. Toyoshima O, Tanikawa C, Yamamoto R, Watanabe H, Yamashita H, Sakitani K, et al. Decrease in PSCA expression caused by Helicobacter pylori infection may promote progression to severe gastritis. Oncotarget. 2018;9(3):3936-45.

52. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000;19(10):1288-96.

53. Tanikawa C, Urabe Y, Matsuo K, Kubo M, Takahashi A, Ito H, et al. A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population. Nat Genet. 2012;44(4):430-4, S1-2.

54. Matsuo K, Tajima K, Suzuki T, Kawase T, Watanabe M, Shiitaka K, et al. Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese. Int J Cancer. 2009;125(8):1961-4.

55. Lu Y, Chen J, Ding Y, Jin G, Wu J, Huang H, et al. Genetic variation of PSCA gene is associated with the risk of both diffuse- and intestinal-type gastric cancer in a Chinese population. Int J Cancer. 2010;127(9):2183-9.
### Table 1
Demographic characteristics of the cases and controls.

| Variables          | Cases (n = 99) | Controls (n = 96) | p  |
|--------------------|---------------|------------------|----|
| Age (years) (mean ± SD) | 67.5 ± 10.9   | 34.3 ± 7         | 0.000 |
| Sex                | n  | %   | n  | %   |     |
| Male               | 64 | 52.9 | 57 | 47.1 | 0.448 |
| Female             | 35 | 47.3 | 39 | 52.7 |     |

### Table 2
Tumor characteristics, including tumor site, tumor grade, lymphatic invasion, perineural invasion, tumor stage and tumor type.

| Characteristic        | Frequency (%) |
|-----------------------|---------------|
| Tumor site            |               |
| Cardia                | 18 (33.3)     |
| Fundus                | 0 (0)         |
| Body                  | 11 (20.4)     |
| Antrum                | 18 (33.3)     |
| Overlapping           | 7 (13.0)      |
| Total                 | 54 (100)      |
| Grade                 |               |
| I                     | 13 (18.8)     |
| II                    | 39 (56.5)     |
| III                   | 17 (24.6)     |
| Total                 | 69 (100)      |
| Lymphatic invasion    |               |
| Present               | 27 (67.5)     |
| Absent                | 13 (32.5)     |
| Total                 | 40 (100)      |
| Perineural invasion   |               |
| Present               | 28 (54.9)     |
| Absent                | 23 (45.1)     |
| Total                 | 51 (100)      |
| T                     |               |
| 1                     | 3 (6.1)       |
| 2                     | 19 (38.8)     |
| 3                     | 26 (53.1)     |
| 4                     | 1 (2.0)       |
| Total                 | 49 (100)      |
| N                     |               |
| 0                     | 19 (36.6)     |
| 1                     | 18 (37.5)     |
| 2                     | 9 (18.8)      |
| 3                     | 2 (4.2)       |
| Total                 | 48 (100)      |
| M                     |               |
| 0                     | 6 (66.7)      |
| 1                     | 3 (33.3)      |
| Total                 | 9 (100)       |
| Stage                 |               |
| I                     | 8 (19.0)      |
| II                    | 16 (38.1)     |
| III                   | 15 (35.7)     |
| IV                    | 3 (7.1)       |
| Total                 | 42 (100)      |
| Tumor type            |               |
| Diffuse               | 14 (73.7)     |
| Intestinal            | 5 (26.3)      |
| Total                 | 19 (100)      |
Table 3
Primer sequences, PCR size and PCR-RFLP fragments using *AIWNI* and *NiaIII* restriction enzymes for *MUC1* 5640G > A (rs4072037) and *PSCA* 5057C > T (rs2294008) polymorphisms, respectively.

| SNP | Primer sequence | PCR Size (bp) | Restriction enzyme | Digestion products (bp) |
|-----|----------------|---------------|--------------------|------------------------|
| MUC1 5640G > A (rs4072037) | F: TAAAGACCCAA CCCTATGACT R: AGAGTACGGCTG CTGGTCATACTC | 188 | *AIWNI* | 188, 114, 74, 188, 114, 74 |
| PSCA 5057C > T (rs2294008) | F: GAAACCCGCTG GTGGTGACT R: GCCAAGCCTGC CATCAACAG | 139 | *NiaIII* | 139, 101, 138, 139, 101, 138 |

Table 4
Comparison of genotype and allele frequencies of *MUC1* gene polymorphisms between gastric cancer patients (n = 91) and normal controls (n = 96) using chi-square analysis.

| SNPa | Genotype/Allele | Controls(n = 96) | Cases(n = 91) | ORb (95% CIc) | P-value |
|------|----------------|-----------------|--------------|---------------|---------|
| MUC1d 5640G > A (rs4072037) | AA | 8 (8.4%) | 4 (4.1%) | - | - |
| | AG | 27 (28.1%) | 58 (63.9%) | 4.296 (1.190-15.517) | 0.018 |
| | GG | 61 (63.5%) | 29 (32%) | 0.951 (0.265-3.417) | 0.938 |
| | AG + GG | 88 (91.6%) | 87 (95.9%) | 1.977 (0.574-6.807) | 0.272 |
| | AG + AA | 35 (36.5%) | 62 (68%) | 3.543 (0.995-12.612) | 0.041 |
| | A | 43 (22%) | 66 (36%) | - | - |
| | G | 149 (78%) | 116 (64%) | 0.507 (0.322-0.799) | 0.003 |

a. Single nucleotide polymorphisms, b. odds ratio, c. confidence interval, d. Mucin 1

Table 5
Comparison of genotype and allele frequencies of *PSCA* gene polymorphisms between gastric cancer patients (n = 99) and normal controls (n = 96) using chi-square analysis.

| SNPa | Genotype/Allele | Controls(n = 96) | Cases(n = 99) | ORb (95% CIc) | P-value |
|------|----------------|-----------------|--------------|---------------|---------|
| PSCAd 5057C > T (rs2294008) | CC | 63 (65.6%) | 62 (62.6%) | - | - |
| | CT | 24 (25%) | 29 (29.3%) | 1.228 (0.644-2.339) | 0.532 |
| | TT | 9 (9.4%) | 8 (8.1%) | 0.950 (0.572-1.579) | 0.844 |
| | CT + TT | 34 (34.4%) | 37 (37.4%) | 1.199 (0.634-2.047) | 0.662 |
| | CT + CC | 90 (90.6%) | 91 (91.9%) | 1.139 (0.634-2.047) | 0.749 |
| | C | 150 (78%) | 153 (77%) | - | - |
| | T | 42 (22%) | 45 (23%) | 1.050 (0.651-1.692) | 0.8398 |

a. Single nucleotide polymorphisms, b. odds ratio, c. confidence interval, * Prostate stem cell antigen
Table 6
Distribution of genotypes MUC1 (rs4072037) and PSCA (rs2294008) polymorphisms according to gender.

| Sex   | Group  | MUC1 5640G > A (rs4072037) | p-value | PSCA 5057C > T (rs2294008) | p-value |
|-------|--------|---------------------------|---------|---------------------------|---------|
|       |        | GG | GA | AA | p-value | CC | CT | TT | p-value |
| Male  | Case   | 18(30.5%) | 40(67.8%) | 1(1.7%) | 0.0001 | 41(64.1%) | 17(26.6%) | 6(9.4%) | 0.92 |
|       | Control| 35(61.4%) | 17(28.9%) | 5(8.8%) |       | 35(61.4%) | 17(29.8%) | 5(8.8%) |     |
| Female| Case   | 11(34.4%) | 18(56.3%) | 3(9.4%) | 0.06  | 21(60.0%) | 12(34.3%) | 2(5.7%) | 0.25 |
|       | Control| 24(61.5%) | 12(30.8%) | 3(7.7%) |       | 28(71.8%) | 7(17.9%)  | 4(10.3%)|     |
3% agarose gel electrophoresis of the restriction enzyme digestion (A) 188 bp PCR fragment of the MUC1 gene restriction enzyme digestion results using AlwNI enzyme; lane 1 and 3 shows homozygous AA, lane 2 heterozygous GA genotype and lane 4 shows homozygous GG genotype respectively, lane 5 shows 100 bp DNA marker (B) Restriction enzyme map of the 139 bp PCR fragment of the PSCA gene using NlaIII enzyme. Lane 1= 100 bp DNA marker, lane 2 heterozygous CT, lane 3 (101 and 39 bp) shows homozygous TT and lane 4, uncut PCR product shows homozygous CC genotype respectively.